Biodexa Pharmaceuticals PLC (BDRX)
| Market Cap | 390.03K |
| Revenue (ttm) | 842,169 |
| Net Income (ttm) | -9.22M |
| Shares Out | 4.92M |
| EPS (ttm) | -0.09 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,313,318 |
| Open | 0.0799 |
| Previous Close | 0.0790 |
| Day's Range | 0.0761 - 0.0849 |
| 52-Week Range | 0.0733 - 20.8000 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jun 20, 2023 |
About BDRX
Biodexa Pharmaceuticals Plc, a drug delivery technology company, focuses on the bio-delivery and biodistribution of medicines in Belgium and internationally. The company is developing MTX110, a direct delivery treatment for diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme; MTD211, a long-acting formulation of brexpiprazole for the treatment of schizophrenia and adjunctive treatment of major depressive disorder; and MTX223, a long-acting injectable formulations of biologic products, such as mAbs or other high molec... [Read more]
Financial Performance
In 2022, BDRX's revenue was 699,000, an increase of 20.93% compared to the previous year's 578,000. Losses were -7.66 million, 40.2% more than in 2021.
Financial numbers in GBP Financial StatementsNews
Biodexa Pharmaceuticals PLC Announces Closing of $3.32 Million Registered Direct Offering
26 May 2023 Biodexa Pharmaceuticals PLC Announces Closing of $3.32 Million Registered Direct Offering Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) (NASDAQ: BDRX), a clinical ...
Biodexa Pharmaceuticals PLC Announces US$3.32 Million Registered Direct Offering
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO CANADA, AUSTRALIA, JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR IN ANY OTHER JURISDICTION IN WHICH OFFE...
Posting of Annual Report & Notice of AGM
Biodexa Pharma ceuticals PLC (“Biodexa” or the “Company”)
Biodexa Pharmaceuticals Enters into Non-binding Letter of Intent for Proposed Acquisition of Varian Biopharmaceuticals
18 May 2023 Biodexa Pharma ceuticals Enters into Non-binding Letter of Intent for Proposed Acquisition of Varian Biopharmaceuticals Biodexa Pharmaceuticals PLC (NASDAQ: BDRX) (“Biodexa” or the “Compan...
Preliminary Results for the Year Ended 31 December 2022
28 April 2023 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company” or, together with its subsidiaries, the “Group”) Preliminary Results for the Year Ended 31 December 202 2 Biodexa Pharmaceuticals ...
Biodexa Pharmaceuticals PLC Announces Exercise of Pre-Funded Warrants & Issue of Equity
Biodexa Pharmaceuticals PLC ("Biodexa" or the "Company") Exercise of Pre-Funded Warrants and Issue of Equity Total Voting Rights ABINGDON, OXFORDSHIRE / ACCESSWIRE / April 20, 2023 / Biodexa Pharmaceu...
Biodexa Pharmaceuticals PLC Announces Issue of Pre-Funded Warrants
Issue of Pre-Funded Warrants ABINGDON, OXFORDSHIRE / ACCESSWIRE / April 3, 2023 / Biodexa Pharmaceuticals PLC (AIM:BDRX.L)(Nasdaq:BDRX), a drug delivery technology company focused on improving the bio...
Biodexa Pharmaceuticals PLC Announces Exercise of Warrants and Issue of Equity
Exercise of Warrants and Issue of Equity Total Voting Rights ABINGDON, OXFORDSHIRE, UK / ACCESSWIRE / March 30, 2023 / Biodexa Pharmaceuticals PLC (AIM:BDRX)(NASDAQ:BDRX), a drug delivery technology c...